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Abstract
Background: Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal
patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete
response in the phase III NEOZOTAC trial. Here we report the results of the secondary endpoints, disease-free survival,
(DFS) and overall survival (OS).
Patients and methods: Patients with HER2-negative, stage II/III breast cancer were randomized to receive the standard
6 cycles of neoadjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy with or without 4mg intravenous
(IV) ZA administered within 24 h of chemotherapy. This was repeated every 21 days for 6 cycles. Cox regression models
were used to evaluate the effect of ZA and covariates on DFS and OS. Regression models were used to examine the
association between insulin, glucose, insulin growth factor-1 (IGF-1) levels, and IGF-1 receptor (IGF-1R) expression with
survival outcomes.
Results: Two hundred forty-six women were eligible for inclusion. After a median follow-up of 6.4 years, OS for all
patients was significantly worse for those who received ZA (HR 0.468, 95% CI 0.226–0.967, P = 0.040). DFS was not
significantly different between the treatment arms (HR 0.656, 95% CI 0.371–1.160, P = 0.147). In a subgroup analysis of
postmenopausal women, no significant difference in DFS or OS was found for those who received ZA compared with
the control group (HR 0.464, 95% CI 0.176–1.222, P = 0.120; HR 0.539, 95% CI 0.228–1.273, P = 0.159, respectively). The
subgroup analysis of premenopausal patients was not significantly different for DFS and OS ((HR 0.798, 95% CI 0.369–
1.725, P = 0.565; HR 0.456, 95% CI 0.156–1.336, P = 0.152, respectively). Baseline IGF-1R expression was not significantly
associated with DFS or OS. In a predefined additional study, lower serum levels of insulin were associated with improved
DFS (HR 1.025, 95% CI 1.005–1.045, P = 0.014).
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Conclusions: Our results suggest that ZA in combination with neoadjuvant chemotherapy was associated with a worse
OS in breast cancer (both pre- and postmenopausal patients). However, in a subgroup analysis of postmenopausal
patients, ZA treatment was not associated with DFS or OS. Also, DFS was not significantly different between
both groups. IGF-1R expression in tumor tissue before and after neoadjuvant treatment did not predict survival.
Trial registration: ClinicalTrials.gov, NCT01099436, April 2010.
Keywords: Breast cancer, Neoadjuvant chemotherapy, Zoledronic acid, Survival, Insulin, IGF-1R
Introduction
Bisphosphonates (BPs) act to suppress bone resorption
by inducing osteoclast apoptosis [1, 2]. BPs are indicated
for treatment and prevention of osteoporosis and pre-
vention of skeletal-related events due to metastasis of
solid tumors or multiple myeloma [3]. Results of the
meta-analysis of the Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) showed that adjuvant BPs
were associated with decreased fracture rate, as well as
improved breast cancer survival and bone metastasis
risk. These benefits were only found in postmenopausal
(natural or induced) women in a subgroup analysis [4].
The benefits may be explained by the increased bone
resorption in postmenopausal patients, as BP prevented
tumor growth in bone in a postmenopausal model but
not in a premenopausal model [5]. Currently, BPs are
considered as a part of the adjuvant breast cancer treat-
ment in postmenopausal patients and patients receiving
ovarian suppression therapy [6]. The exact mechanism
of the anti-tumor effect of BPs is unknown. However,
the following mechanisms have been proposed [7], BPs
may (1) prevent tumors cells from metastasizing to the
bone by decreasing bone turnover [8], (2) change the
bone micro-environment by reducing growth factors
such as insulin-like growth factor-1 (IGF-1) and insulin
and thereby inhibit proliferation [9–12], (3) have immu-
nomodulatory properties by activating γδ T cells [13, 14]
and recruiting tumor-associated macrophages [15, 16],
(4) reduce angiogenic factors [17, 18], and/or (5) kill
dormant disseminated tumor cells [19, 20]. BP was
reported to improve the tumor response when combined
with doxorubicin in an experimental breast cancer
model [21]. Moreover, adding a BP to neoadjuvant
chemotherapy in breast cancer patients resulted in a
significantly lower residual invasive tumor size and a
non-significantly higher pathological complete response
(pCR) rate in an exploratory evaluation of the AZURE
trial [22].
Clinically, in our phase III randomized NEOZOTAC
study examining the effect of zolendronic acid (ZA) in
addition to neoadjuvant TAC chemotherapy in HER2
negative early breast cancer, ZA did not improve the pri-
mary endpoint, pathological complete response (pCR) [23].
A subsequent meta-analysis did not show a significant in-
crease in pCR rate when adding a BP to neoadjuvant
chemotherapy in patients with early breast cancer [16, 24].
In this paper, we report the secondary endpoints of
disease-free survival (DFS) and overall survival (OS) from
the NEOZOTAC study [23].
Additionally, we report associations between the IGF-1
receptor (IGF-1R) expression and the concentrations of
circulating growth factors such as insulin and IGF-1,
and survival. IGF-1R and insulin receptor isoform A (IR-
A) are frequently upregulated in breast cancer [25, 26].
Both receptors activate the Ras/mitogen-activated pro-
tein kinase (MAPK) and phosphatidylinositol-3-kinase
(PI3K)/AKT pathways, through which cell proliferation
is stimulated and apoptosis is inhibited [27].
Methods
Study population
As previously described [23], from July 2010 until April
2012, 250 women participated in the multi-center phase
III NEOZOTAC trial and 246 were evaluated in the
study (2 patients were ineligible and 2 patients withdrew
informed consent; Fig. 1). Eligible patients had a histo-
logically confirmed diagnosis of HER2 negative, stage II
or III (T2 any cN, cM0) early breast cancer, adequate
bone marrow (i.e., white blood cell count ≥ 3.0 × 109/L,
neutrophil count ≥ 1.5 × 109/l, and platelet count ≥
100 × 109/l), normal liver function (i.e., bilirubin ≤ 1.5 ×
upper limit of normal (UNL) range, ALAT and/or ASAT
≤ 2.5 × UNL, alkaline phosphatase ≤ 5 × UNL), adequate
renal function (i.e., calculated creatinine clearance ≥ 50
mL/min), adequate cardiac function, WHO performance
state 0–2, age ≥ 18 years, absence of pregnancy or
current lactation, and written informed consent. Meno-
pause was defined as 1 year without menstrual activity,
previous bilateral oophorectomy, age older than 60 years
or baseline FSH > 20 U/l, and estradiol < 110 pmol/l. The
study (NCT01099436) was conducted in accordance
with the Declaration of Helsinki (October 2008) and was
approved by the Ethics Committee of the LUMC in
agreement with the Dutch law for medical research in-
volving human subjects.
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Treatment
Women received 6 cycles of neo-adjuvant TAC chemo-
therapy (75mg/m2 of docetaxel, 50mg/m2 of doxorubicin
and 500mg/m2 of cyclophosphamide) with or without ZA
(4mg i.v. in 15min within 24 h after chemotherapy, re-
peated every 21 days for 6 cycles). Pegfilgrastim (Neulasta®)
was administered as primary prophylaxis (6mg once per
cycle) as a subcutaneous injection 24 h after chemotherapy
for all cycles. ZA therapy was combined with daily supple-
ments of 500mg calcium and 400 IU vitamin D.
Randomization
Patients were randomized at the LUMC Datacenter of
the Department of Surgery using Pocock’s minimization
technique, stratified by center, clinical T-classification,
clinical N-classification, and estrogen receptor status.
The ALEA randomization program was used.
Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) tumor tissue
samples of pre-chemotherapy biopsies and surgical spec-
imens were collected for analysis of IGF-1R expression
using immunohistochemistry (IHC) (Fig. 1). The staining
method is described extensively elsewhere [25].
Blood sampling and analysis
Non-fasting blood samples were obtained directly before
chemotherapy administration to measure glucose, insulin,
and IGF-1 levels. Samples were collected and kept on ice
directly after drawing. After centrifuging, the supernatant
was stored at − 80 °C and, at the end of the study, was sent
to the Leiden University Medical Center (LUMC) for ana-
lysis. Serum glucose levels were determined by spectro-
photometry (Modular P800, Roche Diagnostics, Almere,
The Netherlands), and insulin levels were analyzed with
the chemiluminescence immunoassay (CIA) (Immulite
2500, Siemens, The Hague, The Netherlands). Serum
levels of IGF-1 (IDS-iSYS) were analyzed with Immunodi-
agnostic Systems (Frankfurt, Germany). The IGF-1 assay
is traceable to the WHO IS 02/254.17.
Endpoints
The primary endpoint of the study was pCR, and the
results of pCR are described elsewhere [23]. PCR was
defined as the absence of residual invasive cancer within
the breast and lymph nodes according to the Miller and
Payne (MP) classification [28]. Secondary endpoints
were DFS, defined as the time from date of inclusion
until the date of the earliest documented local or distant
recurrence, contralateral breast cancer including DCIS,
second primary invasive cancer, or death from any
cause, and OS, defined as the time from inclusion until
date of death from any cause. Additionally, we studied
the association between insulin, glucose, IGF-1 levels,
and IGF-1R expression with survival outcomes.
Fig. 1 Consort diagram of the trial
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Statistical analysis
Median follow-up was calculated by applying the reverse
Kaplan–Meier methodology. Cox regression models were
used to evaluate the effect of ZA and other risk factors on
DFS and OS. Hazard ratios (HRs) and 95% confidence
intervals (95% CIs) were estimated. Relevant risk factors
described in the literature or found to have a P value of
less than 0.1 in univariate analyses were incorporated in
the multivariate model. All tests were two-tailed. P values
of less than 0.05 were considered significant. All analyses




The clinical characteristics of the patients included in
the study are shown in Table 1 and were described pre-
viously [23]. None of these patient characteristics were
significantly different between the two groups. Of the
total cohort, 39.4% had a postmenopausal status at the
start of the study.
Response
The primary endpoint pCR was achieved in 13.3% of the
total cohort. This was not significantly different between
the two arms (P = 0.980). As described previously, pCR
was also not significantly different between the two arms
in a subgroup analysis of postmenopausal women (14.0%
versus 8.7%) [23]. The pCR and recurrence rates are
shown in Table 2. Patients with pCR after neoadjuvant
chemotherapy had a numerically longer period of DFS
Table 1 Patient characteristics
TAC + ZA
N = 122 (49.6%)
TAC
N = 124 (50.4%)
IGF-1R biopsy data available




Median age (range), Years 48.0 (29–67) 49.0 (34–70) 49 (29–70) 49 (34–65)
Median BMI (range), kg/m2 26.1 (18.5–40.0) 25.0 (18.3–42.0) 25.0 (18.3–42.0) 24.9 (19.4–39.5)
Menopausal status
Pre/peri 72 (59.0%) 75 (60.5%) 110 (58.5%) 24 (64.9%)
Post 50 (41.0%) 47 (37.9%) 76 (40.4%) 13 (35.1%)
T-classification
T1/T2 73 (59.8%) 71 (57.3%) 108 (57.4%) 21 (56.8%)
T3/T4 49 (40.2%) 53 (42.7%) 80 (42.6%) 16 (43.2%)
N-classification
N0 54 (44.3%) 56 (45.2%) 90 (47.9%) 22 (59.5%)
N+ 68 (55.7%) 68 (54.8%) 98 (52.1%) 15 (40.5%)
HR-status
ER+ and/or PR+ 101 (82.8%) 104 (83.9%) 158 (84.0%) 33 (89.2%)
ER− and PR− 21 (17.2%) 20 (16.1%) 30 (16.0%) 4 (10.8%)
TAC docetaxel, doxorubicin and cyclophosphamide, ZA zoledronic acid, BMI body mass index, HR hormone receptor, ER estrogen receptor, PR progesterone
receptor, pCR pathologic complete response, LN lymph nodes, MP Miller and Payne
Table 2 Short-term and long-term outcome
Response TAC + ZA
N = 122 (49.6%)
TAC
N = 124 (50.4%)
P value
pCR breast and LN
Yes 16 (13.3%) 16 (13.2%)
No 104 (86.7%) 105 (86.8%) 0.980
Miller and Payne
1 19 (15.8%) 18 (14.8%)
2 35 (29.2%) 31 (25.4%)
3 24 (20.0%) 25 (20.5%)
4 21 (17.5%) 25 (20.5%)
5 21 (17.5%) 23 (18.9%) 0.950
Recurrence
Total 29 (23.8%) 20 (16.1%) 0.134
Local 5 (4.1%) 5 (4.0%) 0.979
Regional 7 (5.7%) 4 (3.2%) 0.341
Distant 27 (22.1%) 17 (13.7%) 0.085
Second primary tumor 5 (4.1%) 5 (4.0%) 0.979
Death
Yes 23 (18.9%) 11 (8.9%)
No 99 (81.1%) 113 (91.1%) 0.023
Cause of death
Breast cancer 22 (95.7%) 11 (91.6%) 0.630
Other 1 (4.3%) 1 (8.3%)
TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid, pCR
pathologic complete response, LN lymph nodes, MP Miller and Payne
the italicized data have a significance of > 0.05
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(HR 0.253, 95% CI 0.061–1.041, P = 0.057), but OS was
not associated with pCR (HR 0.389, 95% CI 0.093–1.624,
P = 0.195) (Fig. 2a, b).
Survival outcomes
The median follow-up was 6.43 years (95% CI 6.25–6.61).
Kaplan–Meier curves of survival rates are shown in Fig. 2.
Risk factors associated with survival as described in the
literature and those with P < 0.1 in univariate analyses
were included in the regression model for multivariate
analysis of mortality determinants. A Cox model was used
to study the associations between risk factors and survival
outcomes. The estimated HRs and associated 95% confi-
dence intervals for univariate and multivariate analyses for
OS and DFS are shown in Tables 3 and 4, respectively.
Age, hormone receptor status, T status, N status, and
Fig. 2 Kaplan–Meier curves of overall survival (left column) and disease free-survival (right column) for pCR (a and b), for treatment with or
without zoledronic acid (c and d), and IGF-1R expression before neoadjuvant chemotherapy (e and f). Note: P-values are given for the univariate
analyses of the Cox regression analyses. Bold values indicate that P < 0.05. Abbreviations: IGF-1, insulin-like growth factor 1; DFS, disease-free
survival; OS, overall survival, pCR, pathological complete response
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menopausal status were adjusted for in the multivariate
Cox model. Women who received ZA had a significantly
worse OS than women who did not receive ZA in univari-
ate analyses (HR 0.448, 95% CI 0.218–0.919, P = 0.029)
(Fig. 2c) and in multivariate analyses (HR 0.468, 95% CI
0.226–0.967, P = 0.040). DFS did not significantly differ
between groups in univariate analysis (HR 0.656, 95% CI
0.371–1.160, P = 0.147) (Fig. 2d). In the ZA arm, one
patient died of stage IV lung cancer, and in the control
arm, one patient died of unknown causes. The percentage
of breast cancer deaths was not significantly different
between both arms. In a subgroup analysis of postmeno-
pausal women, the addition of ZA to chemotherapy did
not affect DFS or OS (HR 0.539, 95% CI 0.228–1.273, P =
0.159; HR 0.464, 95% CI 0.176–1.222, P = 0.120, respect-
ively) (Fig. 3a, b). There was also no significant difference
in survival (DFS or OS) between the two arms in the pre-
menopausal subgroup (HR 0.798, 95% CI 0.369–1.725,
P = 0.565; HR 0.456, 95% CI 0.156–1.336, P = 0.152, re-
spectively) (Fig. 3c, d).
IGF pathway analysis
IGF-1R expression data was available for 188 patients
before and 120 patients after chemotherapy treatment.
The clinical characteristics of the patients included in
the IGF pathway analysis are shown in Table 1 and were
described previously [29]. The presence of IGF-1R
expression in the tumor pre-treatment was numerically
related to DFS, but this was not significant (HR 0.549,
95% CI 0.276–1.089, P = 0.086) (Fig. 2e), and it was not
associated with OS (HR 0.562, 95% CI 0.246–1.285, P =
0.172) (Fig. 2f). In patients with HR-positive breast
cancer, the presence of baseline IGF-1R tumor expres-
sion was associated with a better DFS in univariate
analyses (HR 0.433, 95% CI 0.198–0.946 P = 0.036), but
not in multivariate analysis (HR 0.484, 95% CI 0.214–
1.096, P = 0.082). There was no significant association
between the IGF-1R receptor and OS (HR 0.433, 95% CI
0.198–0.946 P = 0.120). Neither the presence of IGF-1R
expression after neoadjuvant chemotherapy nor the
decrease in expression during therapy was related to
survival. Furthermore, treatment with ZA had no influ-
ence on the IGF-1R expression in the surgical specimen
after chemotherapy treatment.
In a subgroup of patients (N = 37), baseline serum levels
of glucose, insulin, and IGF-1 were measured. Patient
characteristics are reported in Table 1. These were not
significantly different compared to the total cohort. Lower
serum insulin levels were associated with improved DFS
(HR 1.025, 95% CI 1.005–1.045, P = 0.014), but not OS
Table 4 Univariate and multivariate Cox models of DFS
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.034 0.998–1.070 0.061 1.036 0.850–2.637 0.043
BMI 0.989 0.930–1.053 0.739
HR status 1.698 0.868–3.323 0.122 1.799 0.916–3.536 0.088
Menopausal status 1.393 0.795–2.442 0.247
cN status 2.724 1.420–5.224 0.003 2.811 1.461–5.407 0.002
cT status 1.569 0.896–2.748 0.115 1.497 0.850–2.637 0.162
Zoledronic acid 0.656 0.371–1.160 0.147
Bold values indicate that P < 0.05
DFS disease-free survival, HR hazard ratio, CI confidence interval, BMI body mass index
the italicized data have a significance of > 0.05
Table 3 Univariate and multivariate Cox models of OS
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age 1.042 0.999–1.086 0.054 1.019 0.962–1.079 0.522
BMI 1.013 0.943–1.088 0.730
HR status 2.019 0.942–4.328 0.071 2.104 0.978–4.529 0.057
Menopausal status 2.133 1.081–4.210 0.029 1.768 0.670–4.665 0.250
cN status 3.921 1.624–9.471 0.002 4.060 1.672–9.859 0.002
cT status 1.680 0.857–3.295 0.131 1.1516 0.763–3.011 0.235
Zoledronic acid 0.448 0.218–0.919 0.029 0.468 0.226–0.967 0.040
Bold values indicate that P < 0.05OS overall survival, HR hazard ratio, CI confidence interval, BMI body mass index
the italicized data have a significance of > 0.05
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(HR 1.073 95% CI 0.953–1.209, P = 0.244). Glucose and
IGF-1 concentrations were not associated with survival.
Discussion
This study found that ZA as an adjunct to neoadjuvant
chemotherapy had no beneficial effect in patients with
stage II/III HER2-negative breast cancer receiving TAC
chemotherapy and, in pre- and postmenopausal patients,
was associated with worse OS, but not DFS. Addition-
ally, in a post hoc analysis, there was no beneficial effect
of ZA in postmenopausal patients. Interestingly, lower
insulin levels were associated with improved DFS, but
not with OS.
The negative impact of ZA on OS when used as an
adjunct to neoadjuvant chemotherapy was not expected,
as several studies have shown a benefit of ZA in the
adjuvant setting in postmenopausal women [4]. Our
study population may explain the negative impact of ZA
on survival, as the majority (59.8%) of patients were pre-
menopausal. Accordingly, the Azure trial showed that
ZA in the adjuvant setting was associated with worse
DFS and OS in a subgroup of patients younger than 40
years old, who are presumably largely premenopausal.
[30]. However, we also did not find a benefit in post-
menopausal patients.
Moreover, a major difference between adjuvant and
neo-adjuvant use of BPs is the length of administration.
Neoadjuvant BPs are administered for a shorter time
period and therefore may not positively impact survival
outcomes. In the JONIE1 trial, ZA did not have a benefi-
cial effect on survival in the neoadjuvant setting [31],
although the authors did find a positive association with
pCR in previous studies [32]. In keeping with our results,
a meta-analysis of four studies did not show any effect
of ZA addition to neoadjuvant chemotherapy on pCR
rate [16].
In a predefined additional exploratory side study, lower
serum insulin levels were associated with improved DFS.
In keeping with this result, patients with insulin levels
greater than 13 μIU/mL had a twofold increased risk for
disease progression compared to patients with insulin
levels below this cut-off [33]. Goodwin et al. found that
higher fasting insulin levels at baseline in breast cancer
patients without diabetes were also associated with worse
OS [34]. Higher insulin levels may give the tumor a
growth advantage, as most breast tumors express the IGF-
Fig. 3 Kaplan–Meier curves of overall survival (left column) and disease-free survival (right column) for pre/perimenopausal women (a, b) and
postmenopausal women (c, d). P values are given for the univariate analyses of the Cox regression analyses. DFS, disease-free survival; OS, overall survival
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1R and IR-A, both of which are involved in proliferation
and tumorigenesis and are associated with tumor progres-
sion [27, 35].
Our study has some limitations. We are aware that the
sample size is small and the results should therefore be
interpreted with caution. The majority of the patients
included in this study were premenopausal women, but
the positive effect of ZA on survival would be expected
in postmenopausal women. Our post hoc analyses of
postmenopausal women are not statistically powered,
making it impossible to draw firm conclusions. Patients
using BPs at baseline were excluded; however, the use of
adjuvant BPs might have influenced the survival out-
come, but this information is not available in our study.
The sample size of the additional exploratory study of
growth factors was small. However, the results of our
study provide further evidence of the importance of the
insulin and IGF-1R pathway in breast cancer.
Conclusion
Our study does not support the use of ZA as an adjunct
to neoadjuvant chemotherapy in patients with breast
cancer.
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